stem-cell-therapy-parkinsonism

Stem Cell Therapy for Atypical Parkinsonism

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">stem-cell-therapy-parkinsonism</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Cell Source</td>
</tr>
<tr>
<td class="label">Kyoto University (Japan, NCT04995081)</td>
<td>iPSC-derived DA progenitors</td>
</tr>
<tr>
<td class="label">Bemdaneprocel (BlueRock/Bayer)</td>
<td>hESC-derived DA progenitors</td>
</tr>
<tr>
<td class="label">STEM-PD (Lund/Cambridge, NCT05635409)</td>
<td>hESC-derived DA neurons</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Cell Source</td>
</tr>
<tr>
<td class="label">Various MSC trials</td>
<td>Bone marrow/umbilical cord MSC</td>
</tr>
<tr>
<td class="label">Cynata Therapeutics</td>
<td>Allogeneic MSC (iPSC-derived)</td>
</tr>
</table>

Introduction

Stem Cell Therapy for Atypical Parkinsonism

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">stem-cell-therapy-parkinsonism</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Cell Source</td>
</tr>
<tr>
<td class="label">Kyoto University (Japan, NCT04995081)</td>
<td>iPSC-derived DA progenitors</td>
</tr>
<tr>
<td class="label">Bemdaneprocel (BlueRock/Bayer)</td>
<td>hESC-derived DA progenitors</td>
</tr>
<tr>
<td class="label">STEM-PD (Lund/Cambridge, NCT05635409)</td>
<td>hESC-derived DA neurons</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Cell Source</td>
</tr>
<tr>
<td class="label">Various MSC trials</td>
<td>Bone marrow/umbilical cord MSC</td>
</tr>
<tr>
<td class="label">Cynata Therapeutics</td>
<td>Allogeneic MSC (iPSC-derived)</td>
</tr>
</table>

Introduction

Atypical parkinsonian disorders—collectively known as Parkinson-plus syndromes—represent a group of neurodegenerative diseases characterized by parkinsonism (bradykinesia, rigidity, tremor) accompanied by additional neurological features that distinguish them from [Parkinson's disease](/diseases/parkinsons-disease). These include:

• [Progressive supranuclear palsy (PSP)](/diseases/psp): Characterized by vertical gaze palsy, postural instability, and cognitive decline
• [Corticobasal syndrome (CBS)](/diseases/corticobasal-syndrome): Featuring asymmetric rigidity, apraxia, alien limb phenomena, and cortical sensory loss
• [Multiple system atrophy (MSA)](/diseases/multiple-system-atrophy): Divided into MSA-P (parkinsonian) and MSA-C (cerebellar) subtypes, with autonomic dysfunction
• [Dementia with Lewy bodies (DLB)](/diseases/dementia-with-lewy-bodies): Fluctuating cognition, visual hallucinations, and parkinsonism

Rationale for Cell Therapy in Atypical Parkinsonism

Dopaminergic Neuron Replacement

The foundational rationale for stem cell therapy in parkinsonian disorders stems from the successful proof-of-concept established in Parkinson's disease: replacing lost dopaminergic neurons can restore motor function. While atypical parkinsonism involves additional neurotransmitter systems and brain regions, dopaminergic neuron transplantation may still provide symptomatic benefit for the parkinsonian components of these disorders.

Current clinical trials in Parkinson's disease have demonstrated that both [embryonic stem cell (ESC)-derived](/therapeutics/stem-cell-therapy) and [iPSC-derived](/therapeutics/stem-cell-therapy) dopaminergic progenitors can survive, produce [dopamine](/entities/dopamine), and improve motor symptoms[@takahashi2025][@bluerock2024]. These advances provide a foundation for addressing the dopaminergic deficit in atypical parkinsonism.

Neuroprotective and Trophic Support

Beyond direct cell replacement, stem cells—particularly [mesenchymal stem cells (MSCs)](https://en.wikipedia.org/wiki/Mesenchymal_stem_cell)—exert neuroprotective effects through:

• Paracrine secretion of neurotrophic factors: [BDNF](/proteins/bdnf-protein), [GDNF](/proteins/gdnf-protein), NGF, and VEGF
• Immunomodulation: Suppression of pro-inflammatory [microglia](/cell-types/microglia) and reduction of [neuroinflammation](/mechanisms/neuroinflammation)
• Anti-apoptotic effects: Secretion of factors that protect surviving neurons from cell death
• Promotion of endogenous repair: Stimulation of native neural stem cell proliferation and differentiation

Disease-Specific Considerations

Each atypical parkinsonian disorder presents unique considerations for cell therapy:

Progressive Supranuclear Palsy: Neurodegeneration extends beyond the basal ganglia to include the subthalamic nucleus, pedunculopontine nucleus, and brainstem structures. While dopaminergic cell therapy may address bradykinesia and rigidity, the oculomotor deficits and gait freezing require approaches targeting additional neuronal populations.

Corticobasal Syndrome: Asymmetric cortical and subcortical degeneration affects frontoparietal regions. Cell therapy approaches may need to consider both motor cortex involvement and the cognitive deficits associated with cortical pathology.

Multiple System Atrophy: Both MSA-P and MSA-C involve autonomic dysfunction related to brainstem and spinal cord pathology. Cell therapy must address the broader neurodegenerative process affecting multiple neurotransmitter systems.

Dementia with Lewy Bodies: The presence of [alpha-synuclein](/proteins/alpha-synuclein) pathology throughout the cortex and peripheral nervous system presents challenges for cell replacement, though cholinergic neuron replacement may benefit cognitive symptoms.

Stem Cell Types and Applications

Induced Pluripotent Stem Cells (iPSCs)

iPSC technology offers particular advantages for atypical parkinsonism:

• Patient-specific modeling: iPSCs derived from patients can reveal disease-specific mechanisms
• Autologous transplantation potential: Patient-derived cells may reduce immune rejection risk
• Genetic correction: CRISPR-based gene editing can correct disease-causing mutations before transplantation (e.g., in [GBA](/genes/gba)-associated cases)

Embryonic Stem Cells (ESCs)

ESC-derived dopaminergic neurons are the most advanced cell therapy approach currently in clinical development:

• Bemdaneprocel (BlueRock Therapeutics): hESC-derived dopaminergic progenitors in Phase III for Parkinson's disease[@bluerock2024]
• STEM-PD: European trial of hESC-derived dopaminergic neurons[@lund2024]

Mesenchymal Stem Cells (MSCs)

MSCs offer a different therapeutic mechanism focused on neuroprotection rather than cell replacement:

• Delivery routes: Intravenous, intrathecal, or intracerebral administration
• Mechanisms: Paracrine trophic support, immunomodulation, anti-inflammatory effects
• Clinical trials: Multiple trials in Parkinson's disease and ALS have established safety

Neural Stem Cells (NSCs)

Endogenous or derived neural stem cells can differentiate into multiple neuronal subtypes:

• Potential to replace multiple neurotransmitter systems affected in atypical parkinsonism
• Support for circuit reconstruction through axon guidance
• Limited clinical development to date but active preclinical research

Clinical Trial Landscape

Current Parkinson's Disease Trials (Foundational)

Bemdaneprocel (exPDite-2, NCT05887418)

Sponsor: BlueRock Therapeutics (Bayer subsidiary)

Phase: Registrational Phase III (pivotal for approval)

Enrollment: ~102 patients at 24+ clinical sites internationally

Inclusion criteria:

• Age 50-75 years
• Parkinson's disease diagnosis with Hoehn & Yahr stage II-III
• Motor complications inadequately controlled by levodopa
• No significant psychiatric or cognitive impairment
• Able to undergo stereotactic brain surgery

Expected readout: 2027-2028

Access options:

• Enroll in Phase III trial (clinicaltrials.gov NCT05887418)
• Expanded access program (contact BlueRock Medical Affairs)
• Post-approval access upon registration

STEM-PD (NCT05635409)

Sponsor: Lund University / University of Cambridge

Phase: Phase I/IIa, first-in-human

Clinical sites:

• Skåne University Hospital, Lund, Sweden
• UK sites (MHRA approved October 2023)

• Cohort 1 (completed): 4 patients, 3.5M cells per putamen (7M total), lower dose
• Cohort 2 (dosing underway): 4 patients, 7M cells per putamen (14M total), higher dose; first patient transplanted during 2024

• No concerning side effects reported; all patients doing well
• PET imaging at 6-12 months post-transplantation shows signs of dopamine cell survival
• 100,000-200,000 surviving dopamine neurons observed
• 36-month follow-up planned

Kyoto University iPSC-DA Trial (NCT04995081)

Sponsor: Kyoto University / Center for iPS Cell Research and Application (CiRA)

Phase: Phase I/II, completed

Cell source: Autologous iPSC-derived midbrain dopamine progenitors

Results (published Nature 2025):

• 44.7% increase in putaminal dopamine on PET at 12 months
• Safety confirmed over 12-month observation period
• First-in-human demonstration of iPSC-derived DA neuron transplantation

Emerging Programs

Anticipated Applications in Atypical Parkinsonism

Based on the Parkinson's disease foundation, clinical trials for atypical parkinsonism are expected to follow phases:

The choice of disorder for initial trials will likely prioritize:

• PSP: Relatively focal brainstem involvement, clear outcome measures (vertical gaze, postural stability)
• CBS: Asymmetric presentation adds complexity but clear motor endpoints
• MSA-P: Similar to Parkinson's disease with autonomic complications

• Monitor PD trials as leading indicators of cell therapy feasibility
• First CBS/PSP-specific stem cell trials are expected approximately 2-3 years behind PD registrational timelines
• Autologous iPSC programs (Japan) may offer near-term access via research protocols

Transplantation Approaches

Stereotactic Intracerebral Injection

The standard delivery method for dopaminergic progenitors:

• Target: [Putamen](/brain-regions/putamen) primarily, with potential for substantia nigra
• Technique: Multiple injection tracks for broad coverage
• Advantages: Direct delivery to target region, high local cell concentration
• Challenges: Invasive neurosurgical procedure, risk of hemorrhage

Intravenous Administration

Common for MSC-based therapies:

• Target: Systemic, with cells migrating to sites of inflammation
• Technique: Peripheral infusion
• Advantages: Minimally invasive, suitable for repeated dosing
• Challenges: [Blood-brain barrier](/entities/blood-brain-barrier) limits CNS delivery, trapped in peripheral organs

Intrathecal Administration

Delivery into cerebrospinal fluid:

• Target: CSF-exposed brain surfaces and spinal cord
• Technique: Lumbar puncture or cisterna magna injection
• Advantages: Bypasses blood-brain barrier, broader distribution than intracerebral
• Challenges: Variable distribution, risk of infection

Combination Approaches

Emerging strategies combine multiple delivery methods:

• Initial intracerebral transplantation for cell replacement
• Follow-up intravenous or intrathecal MSC administration for neuroprotection
• Repeated dosing schedules to maintain therapeutic effects

Immunological Considerations

Allogeneic Transplantation

Current clinical trials use allogeneic (donor-derived) cells:

• Immunosuppression required: Tacrolimus, mycophenolate mofetil, or similar regimens
• Risks: Infection, metabolic side effects, long-term immunosuppression complications
• Benefits: Off-the-shelf availability, established manufacturing

Autologous Approaches

iPSC technology enables patient-derived cells:

• Reduced immunosuppression: Theoretical advantage of patient-matched cells
• Challenges: Manufacturing complexity, cost, time (several months for reprogramming)
• Current status: Not yet in clinical trials for neurodegeneration

HLA Engineering

Emerging technologies to create universal donor cells:

• HLA knockout: Removing HLA expression to reduce immune recognition
• HLA-E expression: Inhibiting NK cell responses
• Potential: Off-the-shelf cells with minimal immunosuppression

Challenges and Limitations

Disease-Specific Challenges

Technical Challenges

Long-Term Considerations

Emerging Research Directions

Gene-Enhanced Stem Cells

Combining gene editing with stem cell therapy:

• Stress resistance: Engineering cells to resist oxidative stress and excitotoxicity
• Enhanced trophic factor secretion: Engineering MSCs to produce higher levels of [GDNF](/proteins/gdnf-protein) or [BDNF](/proteins/bdnf-protein)
• Disease-modifying secretion: Engineering cells to secrete alpha-synuclein antibodies or tau-targeted molecules

Biomaterial Scaffolds

3D scaffolds to support cell survival and integration:

• Hydrogel carriers: Provide structural support and controlled release of trophic factors
• Biodegradable matrices: Support initial survival while allowing natural integration
• Organoid systems: More complex tissue constructs for transplantation

Combination Therapies

Stem cell therapy combined with other approaches:

• With small molecules: Pharmacological support for cell survival and integration
• With immunotherapy: Targeting pathological proteins to protect grafts
• With physical therapy: Rehabilitation to enhance functional recovery

See Also

• [Stem Cell Therapy for Neurodegenerative Diseases](/therapeutics/stem-cell-therapy)
• [Parkinson's Disease Treatment](/therapeutics/parkinsons-disease-treatment)
• [Progressive Supranuclear Palsy](/diseases/psp)
• [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Gene Therapy for Neurodegeneration](/therapeutics/aav-gene-therapy-neurodegeneration)
• [Trophic Factor Therapy](/therapeutics/gdnf-therapy-neurodegeneration)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1

Related Analyses:

• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;